HUGE congrats to Arielle Elkrief, MD FRCPC Smruthy Sivakumar Marc Ladanyi #CharlesRudin Chad Vanderbilt, MD & the exceptional teams at Memorial Sloan Kettering Cancer Center Foundation Medicine Flatiron Health that put together this massive effort in Journal of Clinical Oncology, characterizing the #intratumoral #microbiome in #lungcancer. While

Link to paper in Journal of Clinical Oncology here: ascopubs.org/doi/10.1200/JC…

Afamicel, TCR targeting MAGEA-4 approved for #synovial sarcoma. A remarkable advancement for our patients, laying the foundation for future efforts in solid tumors. businesswire.com/news/home/2024…

The CEO of Texas Children's Mark Wallace made a salary of +3 million in 2021 and it increased to 8 MILLION in 2022 They just laid off 1,500+ people. They’re also reducing ICU nurses pay by $12 per hour, a permanent increase that was given for retention in 2021 Criminal 🧵1/

A novel treatment paradigm for this notoriously difficult to treat sarcoma. #DSRCT #HER2 ADCs By Tom Zhang, Christopher Febres-Aldana, MD, Raymond DeMatteo, PharmD, BCOP, Allan Lui,Igor Odintsov et al under the leadership of Dr.Romel Somwar and Marc Ladanyi. Clinical Cancer Research aacrjournals.org/clincancerres/…

DSCRT, extremely rare, poor prognosis. Glad to see Marc Ladanyi continuing to make inroads to treatments pubmed.ncbi.nlm.nih.gov/39120576/.

1. This summer I've been thinking a lot about "cognitive load" which is term that has multiple definitions but for me means something like "the amount of processing, analysing, thinking, & deciding I can do in a day before my brain stops working" here's a short thread about that

3. One way being in academia has changed over the years is that the cognitive load we all face, at all career stages, has increased. Constant emails, text msgs, online trainings, paper work, the number of papers published, the # of things competing for our attention is staggering

7. Here's some examples: make it a policy to try & reduce meetings & emails to a bare minimum. Have clear boundaries around tasks & jobs, make sure academics have admin support that is empowered & trusted by the institutions to make decisions, encourage less but smarter oversight

Nice to see this overview of biology of histological transformation that we see in patients with lung cancer by Alvaro Quintanal-Villalonga in Science Translational Medicine science.org/doi/10.1126/sc…

#MSKimpact ... the gift that keeps on giving: rdcu.be/dQ4bp

Looking to start a new project? Avoid the cargo cult fallacy & the familiarity, over-specialization and popularity biases. These are taken directly from Michael Fischbach’s (Michael Fischbach) wonderful article from earlier this year (with slight modifications). 🧵⬇️ cell.com/cell/abstract/…

Now online in Cancer Discovery: #Chromothripsis-mediated Small Cell Lung Carcinoma - by Natasha Rekhtman MD PhD Sam T Christopher Febres-Aldana, MD Charlie Rudin and colleagues doi.org/10.1158/2159-8… Memorial Sloan Kettering Cancer Center #SCLC

Was lucky to join this team! A rare subgroup of SCLC originates from carcinoids. Surprisingly, their genomic hallmark was whole-chromosomal chromothripsis amplifying oncogenes. Thanks and congrats to my mentors and the leads Charlie Rudin Natasha Rekhtman MD PhD Sam T Christopher Febres-Aldana, MD

Charlie Rudin Natasha Rekhtman MD PhD Sam T Christopher Febres-Aldana, MD An example of shattering three chromosomes and putting the pieces together to form 1) derivative chromosomes and 2) ecDNAs amplying oncogenes. Not a cherry-picked case, was rather a general pattern in these cases. Still surprising that this has happened early in their oncogenesis

Our paper on a new approach to precision radiotherapy -- “Genotype-Directed Synthetic Cytotoxicity of ATR Inhibition with Radiotherapy” led by Victor Ng and Sonali Sinha is out in Clinical Cancer Research #radonc #radbio (1/N) aacrjournals.org/clincancerres/…

1 Hot off the press from team Memorial Sloan Kettering Cancer Center in Cancer Discovery! A study solving the puzzle of exceptional new lung cancer type: #Chromothripsis-mediated Small Cell Lung Cancer #SCLC This took nearly a decade and 42 coauthors to unravel. Here are some highlights 👇

Fusion variant-specific tumor suppressors in ALK+ lung cancers. SETD2 inactivation conferred a larger impact on tumorigenesis in the context of EML4-ALK v3 (fusing exon 6 of EML4 and exon 20 of ALK) than v1 (e13-e20).

Nice paper that goes deep into the loose correlation between mRNA & protein abundances and does some sensible adjustments/featurizations of mRNA to make it a better predictor of protein. Also very handy numbers here (median 17 mRNA vs. 50k protein copies per cell)

Please join me and Dr. Jamie Chaft as we explore the latest updates in actionable biomarkers in early-stage NSCLC this Monday, September 9, 2024 at 12:30 PM PDT (Room: 33ABC) #WCLC24